Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items: 2021-2025

Historic Non-cash Items for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $52.6 million.

  • Amylyx Pharmaceuticals' Non-cash Items rose 1940.61% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.6 million, marking a year-over-year increase of 1940.61%. This contributed to the annual value of $3.7 million for FY2024, which is 5.32% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Non-cash Items of $52.6 million as of Q3 2025, which was up 979.31% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Non-cash Items ranged from a high of $201.8 million in Q4 2022 and a low of $287,000 during Q2 2024.
  • Moreover, its 3-year median value for Non-cash Items was $3.5 million (2023), whereas its average is $9.6 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Non-cash Items crashed by 95.14% in 2023 and then surged by 1,940.61% in 2025.
  • Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Non-cash Items stood at $15.6 million in 2021, then surged by 1,191.13% to $201.8 million in 2022, then tumbled by 86.30% to $27.6 million in 2023, then crashed by 86.72% to $3.7 million in 2024, then surged by 1,940.61% to $52.6 million in 2025.
  • Its last three reported values are $52.6 million in Q3 2025, $4.9 million for Q2 2025, and $4.1 million during Q1 2025.